| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.raymedlab.com | |
| Market Cap | 1.02 Cr. | |
| Enterprise Value(EV) | 1.02 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.31 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.99 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | -5.52 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | -0.43 | Calculated using Price: 2.39 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.43 Cr. | 4,273,500 Shares |
| FaceValue | 10 | |
| About Raymed Labs Ltd. | ||
| Raymed Labs was established in 1994 as a pharmaceutical company with emphasis on injectables with state of the art manufacturing facilities. the company is located at Dehradun Road, Saharanpur, UP. Manufacturing pharmaceutical products, as such, is a specialized job, however, manufacturing of injectables is even more difficult since they are normally given during a life saving situation thus their quality standards are much more stringent. Raymed's quality quickly won the trusts of doctors and it established itself as one of the leading quality manufacturers of medicines in the area. | ||
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
+14.90% |
| 3 Month |
|
-2.45% |
| 6 Month |
|
-2.85% |
| 1 Year |
|
+17.16% |
| 2 Year |
|
+44.85% |
| 5 Year |
|
+4.37% |
| 10 Year |
|
-74.84% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Return on Capital Employed (%) | -7.11 | -15.55 | -26.39 | -41.34 | -58.42 | -105.49 | -94.35 | 0 | 0 | |
| Return on Assets (%) | -6.08 | -12.9 | -17.98 | -20.71 | -20.01 | -21.34 | -27.07 | -32.96 | -85.07 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | |
| Non Curr. Liab. | 2 | 2 | 2 | ||||||||
| Curr. Liab. | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Non Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | |||||||||||
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | |||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Taxation | |||||||||||
| Exceptional Items | 0 | 0 | 0 | 0 | |||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | -2 | 0 | ||||||
| Cash Fr. Inv. | 0 | 2 | 0 | ||||||||
| Cash Fr. Finan. | 0 | 0 | 0 | ||||||||
| Net Change | 0 | ||||||||||
| Cash & Cash Eqvt |
|
Wed, 17 Apr 2024
Announcement under Regulation 30 (LODR)-Change in Registered Office Address Outcome of Board Meeting pursuant to under Regulation 30 of SEBI (LODR) Regulations 2015- change in Registered office of the Company within Local Limits |
|||||||||||||||||||||
|
Mon, 15 Apr 2024
Compliance Under Reg. 40(9) Of SEBI (LODR) Regulations 2015 Compliance under Reg. 40(9) of SEBI (LODR) Regulations 2015 for the year ended 31 March 2024 |
|||||||||||||||||||||
|
Sat, 13 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Shreya Dave Designation: Company Secretary and Compliance Officer EmailId: raymedlabs@rediffmail.com Name of the Chief Financial Officer: Ajai Goyal Designation: Chief Financial Officer EmailId: raymedlabs@rediffmail.com Date: 13/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Mon, 22 Apr 2024 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Opening at High
|
Opening at Low
|
